Key result
Advances in medical and surgical therapy have improved the life expectancy of patients with Marfan syndrome from 40-50 years in the 1970s to comparable to that of the general population.
Advances in medical and surgical management have dramatically improved the life expectancy of patients with Marfan syndrome.
Affirms benefits of modern therapies in Marfan syndrome; leaves open need for updated prospective survival data.
gene (reported in 1991). In the 1970s, the life expectancy of people with MFS was 40-50 years, mainly due to increased risk of aortic dissection or heart failure from aortic or mitral regurgitation. However, due to advances in medical and surgical therapy, life expectancy has improved dramatically and is now comparable to that of the general population. We discuss the cardiac manifestations of MFS, the incidence of arrhythmia in this population, the standard of medical care for arrhythmia and valve insufficiency, and a new use of preventive medication to preserve the integrity of the aortic wall in patients with MFS.
No takes yet. Share an insight, caveat, or question.
Isekame et al. (2016) conducted a review in Marfan Syndrome. Advances in medical and surgical therapy have improved the life expectancy of patients with Marfan syndrome from 40-50 years in the 1970s to comparable to that of the general population.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: